Ireland
--:--IST
Recruiting Not applicable

The Radium-select Study

NCT06659926 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2025-02-24
Last updated
2025-07-08

Condition(s) studied

mCRPCMale Urogenital Diseases

Investigational drug(s) / intervention(s)

68Ga-PSMA-PET/CT scan

68Ga-PSMA-PET/CT scan: 68Ga-PSMA-PET/CT scan at baseline and will be followed throughout the treatment with online patient reported outcome measure (PROM) questionnaires (Kaiku application) and blood sampling for circulating tumor DNA (ctDNA) analysis. At clinical progression, each patient will undergo a second 68Ga-PSMA-PET/CT to determine the location of disease progression and assess the value of 68Ga-PSMA-PET/CT imaging as a response measure

Study summary

Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis. Patients are eligible for this treatment when they have mCRPC and bone metastases; limited extraskeletal lesions (local prostate, lymph nodes \<3 cm) on conventional contrast enhanced CT (ceCT) were allowed in the registration trial(1). Previous research revealed that extraskeletal disease on ceCT and bone scans correlates with a poor response. Meanwhile, 68Ga-PSMA-PET/CT emerged as more sensitive imaging strategy that increases the detection of extraskeletal prostate cancer metastases. It is unclear whether these extraskeletal lesions harbour any predictive value in the treatment of mCRPC patients with Radium-223.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate. * Progressive disease after previous treatment defined as a rise in serum (Prostate Specific Antigen) PSA (PCWG3 criteria(22), see appendix 1) and/or progression on conventional imaging (PCWG3). * A positive bone scan (osteoblastic bone metastases), with at least two metastases. * Hemoglobin concentration \>10 g/dl (6.2 mmol/l) and thrombocytes \>100 109/I at baseline. * Each patient will need to (continue to) receive adequate bone protective agents (e.g. bisphosphonates) and androgen deprivation therapy (ADT) according to current clinical guidelines. Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance score \>2 * Life expectancy \< 6 months. * Detected extra-skeletal metastases or lymph node metastases (\>3 cm short axis) as identified by conventional imaging (ceCT thorax/abdomen)

Primary outcome measure(s)

  • Clinical progression free survival (cPFS) — Up to 28 weeks
    The primary study endpoint will be clinical progression free survival (cPFS) in 30 patients with bone-only disease according to PSMA PET/CT.

Trial sites (5)

FacilityCityRegionStatus
NKI-AVL Amsterdam North Holland Recruiting
Meander Medisch Centrum Amersfoort Utrecht Recruiting
Sint Antonius ziekenhuis Nieuwegein Utrecht Recruiting
Diakonessenhuis Utrecht Netherlands Not Yet Recruiting
UMC Utrecht Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06659926 on ClinicalTrials.gov ↗ ← All trials in the Netherlands